Investor Service Announcement no.2/2011
To: NASDAQ OMX Copenhagen Hørsholm, Denmark, May 4, 2011
LifeCycle Pharma A/S to Host Conference Call Announcing
Result for the first quarter 2011
LifeCycle Pharma A/S (OMX: LCP) will announce the result for the first quarter 2011 on Tuesday May 10, 2011 after 5 PM. LCP’s Management will host a conference call on May 11, 2011, at 3:00 PM CET (Denmark); 2:00 PM GMT (London), 9:00 AM ET (New York), 6:00 AM PT (San Francisco) to discuss the financial results.
To access the live conference call, please dial one of the following numbers:
+45 32 72 76 25 Denmark
+44 (0) 1452 555 566 UK
+1 631 510 7498 USA
Access code 64356225
Following the conference call, an audio cast will be available on the company’s website www.lcpharma.com until June 10, 2011. A presentation will be available on LCP’s website (under ‘Investors’) one hour prior to the scheduled time of the conference call.
For more information, please contact:
|
LifeCycle Pharma A/S John Weinberg, M.D. SVP, Commercial Operations & Investor Relations Phone: +1 732 321 3208 Email: jdw@lcpharma.com |
Johnny Stilou CFO Phone: + 45 2055 3817 Email: jst@lcpharma.com |
About LifeCycle Pharma A/S (LCP)
Based in Hørsholm, Denmark, with an office in New Jersey, LCP is a specialty pharmaceutical company. Clinical development is the core of LCP's efforts to develop a product portfolio which includes the Company’s lead product candidate, LCP‐Tacro™, for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. LCP adapts new technologies on a fast commercial timetable. LCP's unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability ‐ at low‐scale up costs ‐ not only for a broad spectrum of drugs already on the market but also for new chemical entities. LCP has a lipid lowering product, Fenoglide®, currently on the U.S. market and a diversified near and medium term pipeline with three clinical stage product candidates and a number of projects in preclinical development. LCP is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: LCP. For further information, please visit www.lcpharma.com
